This finding was published in April, 1983, using the hamster as a model ( Inhibition of GLP-1 Inactivation to Take Use of Its Glucose-Lowering Action The challenge in the early 1990s of using GLP-1 as a glucose-reducing agent was its rapid inactivation which results in a short half-life of the peptide
L-Carnitine is known to increase fat-burning (fat oxidation) and energy levels in patients with conditions ranging from peripheral vascular disease to heart failure and kidney problems (6, 7, 8)
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Sermorelin therapy is not suitable for everyone and may have potential risks and side effects
104,112 Accumulated evidence suggests that both glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may affect renal function in both glucose lowering dependent and independent mechanisms of action
However, palatability remains a challenge, as adherence to plant-based diets is often limited by taste [23]
